anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An emergency patient management system and a method thereof using an RFID tag are provided to manage a position of a doctor by using the RFID tag, thereby confirming a call/response state of the doctor quickly when a call is made from an emergency room. When an RFID tag decides that a patient leaves an emergency room, an entrance information management system(10) outputs location information and an ID of the RFID tag. A tag information manager(12) manages the RFID ID toward an identifier of the RFID tag. An event sensor(16) extracts the RFID identifier and an entrance detection sensor ID from an RFID tag signal received through an AP(Access Point). An entrance information manager(14) generates RFID tag location information where a location of the RFID tag is displayed on a map. An emergency patient safety management system(20') outputs a state that a patient leaves an emergency room, on a display unit(30).
1. Technical Result Possibility of maintenance of pregnancy.          2. Essence Use of progestin as a means for regular withdrawal bleeding under cyclical delivery of progestin comprising daily, cyclical vaginal delivery of progestin via the system of delivery of the medicinal means to the site of effect in the amount sufficient to cause secretory transformation of endometrium for significant decrease in adverse side effects and also pharmaceutical composition containing progestin.          3. Field of Application Medicine.
Study phase 1 (single dosing): 1000 mg once. Study phase 2 (multiple dosing): 1000 mg twice daily for a minimum of 12 and a maximum of 14 days.
Participants were randomized to receive double-blind placebo, two tablets, orally, once daily for 12 weeks in the Treatment Period. Those who completed the Treatment Period continued to receive double-blind placebo once daily in the 2-week Run-out Period.
This arm will comprise of PROP super-taster subjects. Subjects will use a cranberry-derived oral rinse twice a day for 11 days following a 3-day plain water-rinse period.
PURPOSE: Arthrodesis of the first ray metatarsophalangeal joint (MPJ) is the gold standard in iatrogenic hallux varus (IHV) in the presence of stiffness and osteoarthritis. The purpose of this study is to collect clinical and radiographic results and complications of MPJ arthrodesis in rigid iatrogenic HV.
METHODS: A retrospective evaluation of rigid iatrogenic HV undergoing arthrodesis with a minimum follow-up (FU) of two years was performed. The clinical parameters assessed were visual analog scale (VAS), the AOFAS Hallux Metatarsophalangeal-Interphalangeal Scale score and the satisfaction scale. The radiological parameters evaluated the first to second metatarsal angle (IMA) and the angle of hallux valgus (HVA). Complications were also analysed.
RESULT: A total of 18 patients (19 procedures) with a mean FU of 5.5 ± 2.5 years were included. The mean VAS improved from 7.3 ± 1.6 to 1.3 ± 1.2 (p < 0.05) at the last FU. Similarly, the AOFAS Hallux Metatarsophalangeal-Interphalangeal scale score significantly improved to 82 ± 9.2 (p < 0.05). Radiological evaluation demonstrated a 1-2 IMA improvement from 4.4 ± 2.2° preoperatively to 8.9 ± 2.4° at 3 months post-operatively. Similarly, there was a significant (p < 0.05) improvement of the HVA from - 22.7 ± 4.1° to 13.1 ± 4.1° at three months post-operative (p < 0.05). No signification loss of correction was noted at the last follow-up (p > 0.05). In one case, a delayed fusion at the arthrodesis site required surgical revision to promote fusion. No patient experienced pain with stress from the first MTP joint arthrodesis site or identified the arthrodesis site as a source of pain. No patient required implant removal. Re-operation and revision rates were 5.3%. The overall complications rate was 15.8%.
CONCLUSIONS: MPJ fusion effectively corrects Iatrogenic Hallux Varus in cases of rigid and fixed deformities in the medium- to long-term follow-up, with lasting improvements in AOFAS and VAS scores. The procedure is characterised by a non-negligible risk of complications, reoperations and revisions.
LEVEL OF EVIDENCE: Level IV, case series.
Brown adipocytes are defined based on a distinct morphology and genetic signature that includes, amongst others, the expression of the Purinergic 2 Receptor X5 (P2RX5). However, the role of P2RX5 in brown adipocyte and brown adipose tissue function is poorly characterized. In the present study, we conducted a metabolic characterization of P2RX5 knockout male mice; next, we characterized this purinergic pathway in a cell-autonomous context in brown adipocytes. We then tested the role of the P2RX5 receptor agonism in metabolic responses in vivo in conditions of minimal adaptive thermogenesis requirements. Our data show that loss of P2RX5 causes reduced brown adipocyte differentiation in vitro, and browning in vivo. Lastly, we unravel a previously unappreciated role for P2RX5 agonism to exert an anti-obesity effect in the presence of enhanced brown adipose tissue recruitment in male mice housed at thermoneutrality. Altogether, our data support a role for P2RX5 in mediating brown adipocyte differentiation and function that could be further targeted for benefits in the context of adipose tissue pathology and metabolic diseases.
1. A method of perfusing a subject, said method comprising: sequentially introducing to said subject a first and second fluid composition, wherein: (a) said first fluid composition is a conventional biological buffer free nonnaturally occurring plasma-like solution comprising: (i) electrolytes; (ii) an oncotic agent;(iii) and a dynamic buffering system; and (b) said second fluid composition is a fluid blood composition. 2. The method according to Claim 1, wherein said electrolytes include: Na<+>, Mg<2+>, Ca<2+>, and Cl<->. 3. The method according to Claim 2, wherein said non-naturally occurring plasma-like solution further includes K<+>. 4. The method according to Claims 1 to 3, wherein said solution further includes a blood clotting factor. 5. The method according to Claims 1 to 4, wherein said dynamic buffering system comprises an organic carboxylic acid, salt or ester thereof. 6. The method according to Claims 1 to 5, wherein said non-naturally occurring plasma-like solution further includes a sugar selected from the group consisting of monosaccharides and disaccharides. 7. The method according to Claims 1 to 6, wherein fluid blood composition is whole blood or a derivative thereof. 8. The method according to Claim 7, wherein said fluid blood composition is not terminally heat sterilizable. 9. The method according to Claims 1 to 8, wherein said method further comprises the introduction of at least one additional fluid composition. 10. The method according to Claims 1 to 9, wherein said method further comprises reducing the temperature of said subject. 11. The method according to Claims 1 to 10, wherein said method further comprises placing said subject into a hyperbaric environment. 12. A kit for use in a perfusion method, said kit comprising: (a) a conventional biological buffer free synthetic plasma-like solution according to any one of Claims 1 to 8; and (b) instructions for performing the method according to Claim 1. 13. A perfusion system comprising: (a) means for introducing and removing liquid from the circulatory system of a subject; (b) a conventional biological buffer free synthetic plasma-like solution according to any one of Claims 1 to 8; and (c) a fluid blood composition comprising at least one naturally occurring blood component. 14. The system according to Claim 13, wherein said system further comprises a means for modulating the temperature of said subject. 15. The system according to Claim 13 or 14, wherein said system further comprises a means for modulating the pressure of the environment of said subject.
The method of lowering human blood serum cholesterol consists of ingesting or administering to a patient orally once daily before any food intake a mixture of beet juice, lemon juice and bee honey. The mixture is in the proportions of about 1 part by volume of the beet juice, about 1 part by volume of the lemon juice and about 0.4 part by volume of the bee honey, and the total volume of the mixture is about 3.5 ounces. This regimen is carried out until the blood serum cholesterol drops to a safe level, below about 240 mg.dl. The length of time of administration depends on initial cholesterol level. However, in most cases, the treatment period is about 10-17 days. The mixture can be periodically administered thereafter to keep the cholesterol low or to again bring it down.
After successful Endoscopic variceal ligation (EVL) the control group will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly instead of Terlipressin for 2 days. Both the group will receive standard care of therapy.
549,931. Vitamins. OGILVIE FLOUR MILLS CO., Ltd. June 10, 1941, No. 7333. Convention date, Jan. 7. [Class 2 (iii)] [Also in Group V] Saponifiable oils such as wheat germ oil are treated in solution in an organic solvent such as petroleum ether or acetone with cold concentrated (85 per cent.) sulphuric acid, the solvent phase is separated and the solvent removed to recover tocopherol (vitamin E) in relatively concentrated form. The acid phase is diluted with water, the precipitate filtered off and extracted with ethyl ether to yield an oil having anti-oxidant properties and a residue having detergent properties.
Patients receive exemestane PO QD and darolutamide PO BID starting on days -14 to -7 prior to C1D1 and then on days 1-28 of each cycle. Patients receive leuprolide acetate IM on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo chest CT or chest x-ray and CT, MRI, or PET/CT as well as blood sample collection throughout the study. Patients undergo collection of archived tissue during screening.
Meralgia paresthetica is a neurological disorder characterized by a symptom complex of numbness, burning, tingling, aching, or stabbing in the anterolateral portion of the upper thigh. Typically, this disorder is seen in patients with diabetes mellitus, obesity, and pregnancy. Also, it may result from a wide array of surgical interventions involving the region of the anterior superior iliac spine. Underlying pathophysiology concentrates on entrapment neuropathy of the lateral femoral cutaneous nerve (LFCN). Due to its location and wide anatomic variation, the LFCN is susceptible to compression, scarring, and injury during surgery. It is important to understand the regional anatomy. In addition, the plastic surgeon must have a working knowledge of the most common variations that can precipitate entrapment and increase susceptibility to injury during surgery. Surgeons lacking a substantial background on the numerous risk factors, origins, and anatomic variations of the LFCN may place patients at an even higher risk of damage to the nerve. An extensive knowledge of the anatomy and careful technique may be utilized by surgeons to prevent iatrogenic neuropathy of the LFCN.
The present invention relates to pharmaceutical compositions for treating allergic reactions formulated for rapid delivery. In one embodiment, the delivery vehicle is a fast dissolving film. These films contain novel adrenergic prodrugs for rapid treatment of allergic reactions in patients. The present invention relates to pharmaceutical compositions prepared by modifying the physicochemical properties of epinephrine to enhance its permeability through biological membranes (sublingual and buccal). By modifying the two hydroxyl (phenolic) groups at the 3 and 4 positions on the benzene ring, several epinephrine prodrugs are shown by chemically reacting the two groups with several acid moieties to form ester linkages with different alkyl chains. The addition of alkyl groups will enhance the lipophilicity of epinephrine (increase log P) and thus its permeability through biological membranes (sublingual and buccal tissues in the oral cavity).
PURPOSE:To provide the above molding which has resilience and the strength to withstand use, utilizes the characteristics of silkfibroin, is usable adequately for various medical materials and biochemical materials and is improved in dimensional stability to underwater heat by forming the molding of a mixture composed of the silkfibroin and a synthetic high-polymer material. CONSTITUTION:The silkfibroin is dissolved into a thick aq. soln. of calcium chloride (usually 40 to 50% concn.) or dissolved in an aq. soln. of a neutral salt such as satd. aq. soln. of lithium bromide after removing sericin in case of a raw material in which the sericin is contained. This soln. is dialyzed by a semipermeable membrane such as cellophane film to remove the salt. The resulted aq. silkfibroin soln. and an aq. soln. or emulsion of the synthetic high- polymer material are mixed. This liquid mixture is used and is molded by a proper means meeting the desired molding form and if necessary, the molding is heat treated at 200 to 230 deg.C or is immersed into lower alcohol in order to assure insolubilization.
Multiple Organ Dysfunction Syndrome (MODS) frequently leads to death in patients with sepsis. Our previous work has demonstrated that endothelial injury is closely associated with MODS development and mortality in septic patients. The sepsis-induced damage of endothelial cell membrane gives rise to increased capillary permeability. Evidence suggests that increased capillary permeability in patients with sepsis was associated with higher incidence of MODS and death during the ICU stay than those with decreased permeability. Angiopoietin (Ang) system is the key mediator for maintaining capillary permeability. Ang-2 triggers an inflammatory response and inducing permeability by activating the endothelium. In contrast, Ang-1 is anti-inflammatory, can inhibit adhesion molecule expression and attenuate permeability increase in different stimuli. The disrupted angiopoietin system has been reported in patients with sepsis, but the association between angiotension and MODS in septic patients has not been well addressed.

This study is designated to determine serum concentrations of Ang-1, Ang-2, Ang-1/Ang-2 ratio, and Tie-2 in patients with sepsis-induced MODS and to investigate the association among increased permeability, inflammatory mediators,autonomic dysfunction, and these serum mediators in development of organ failure. In addition, the study will incubate endothelial cells with septic patients' serum or tumor necrosis factor (TNF)-alfa, and determine the effects of ang-1 administration and blockade of ang-2 on disruption of endothelial cell structure, permeability increase, and expression of adhesion molecules. The study will also determine the signaling pathways and altered NF-kB dimmer composition that is responsible for the inhibitory effect for ang-1 administration on TNF-alfa-induced intercellular adhesion molecule (ICAM)-1 expression on endothelial surface.
Background: This study aimed to evaluate the effectiveness of implementing an adapted, evidence-based 12-week Family Healthy Weight Program (FHWP), Building Healthy Families, on reducing BMI metrics and clinical health indicators in a real-world community setting. Methods: Ninety child participants with a BMI percentile greater or equal to the 95th percentile for gender and age and their parents/guardians (n = 137) enrolled in the program. Families attended 12 weekly group-based sessions of nutrition education, family lifestyle physical activity, and behavior modification. A pre-post study design with a 6-month follow-up was used. Results: Nine cohorts of families between 2009 and 2016 completed the program with 82.1% retention at 12 weeks and 53.6% at 6 months. Participants had statistically significant improvements at 12 weeks in BMI z-score, %BMIp95, body mass, body fat, fat mass, fat-free mass, and systolic blood pressure with greater improvement at 6 months in body mass, BMI metrics, body fat, fat mass, fat-free mass, and systolic blood pressure. Parents/guardians of the participants had similar statistically significant body composition and blood pressure improvements (p < 0.05). In addition, children had significant improvements in high-density lipoprotein (HDL) cholesterol and aspartate aminotransferase (AST) liver enzymes at 6 months. Conclusions: Overall, this study demonstrated that an evidence-based FHWP can result in statistically meaningful declines in BMI z-score and accompanied clinically meaningful changes in health risk. Participants lost ∼4% of their body mass in 12 weeks, while their parents/guardians lost closer to 7% of their body mass, which supports previous literature suggesting body mass changes influence health.
PCT No. PCT/GB92/01016 Sec. 371 Date Jan. 4, 1994 Sec. 102(e) Date Jan. 4, 1994 PCT Filed Jun. 5, 1992 PCT Pub. No. WO92/21370 PCT Pub. Date Dec. 10, 1992A treatment of fish for infection by the organism Aeromonas salmonicida using either one or both of two components produced by a culture of the organism. The culture is treated to kill the organisms prior to use, preferably by treatment with formalin after the components have been produced. One of the components, only produced when the culture is grown under iron limiting conditions induces production of antibodies which cause death of the organisms when injected intraperitoneally into fish.
RAPAFLO was evaluated at doses of up to 48 mg/day in healthy male subjects. The dose-limiting adverse event was postural hypotension.

Should overdose of RAPAFLO lead to hypotension, support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by maintaining the patient in the supine position. If this measure is inadequate, administration of intravenous fluid should be considered. If necessary, vasopressors could be used, and renal function should be monitored and supported as needed. Dialysis is unlikely to be of significant benefit since silodosin is highly (97%) protein bound.
Provided are a bispecific antibody combination and a use thereof. The bispecific antibody combination comprises a bispecific antibody I and a bispecific antibody II. The bispecific antibody I comprises a CD3-targeting domain and a tumor-associated antigen-targeting domain, and the bispecific antibody II comprises a 4-1BB-targeting domain and a tumor-associated antigen-targeting domain. Further provided are a pharmaceutical composition, a test kit, a kit of parts and an administration device containing the same, and a method of treating cancer by using the same. The concomitant use of the bispecific antibodies not only reduces the exhaustion of T cells, but also significantly facilitates tumor killing at a later stage. Moreover, the concomitant use of the bispecific antibodies, especially when targeting different epitopes of the same tumor-associated antigen or targeting different tumor-associated antigens, produces a strong synergistic killing effect. The use of the bispecific antibody combination and the pharmaceutical composition containing the same provides a potential clinical solution for effectively treating solid tumors.
BACKGROUND: Weight loss is commonly recommended before total knee arthroplasty (TKA) despite inconsistent evidence for better outcomes. This study sought to examine the impacts of preoperative weight loss on patient-reported and adverse outcomes among TKA patients supervised by a medical weight management clinic.
METHODS: This study retrospectively analyzed patients who underwent medical weight management supervision within 18 months before TKA comparing patients who did and did not have clinically relevant weight loss. Preoperative body mass indices, demographics, Patient-Reported Outcomes Measurement Information System physical function and pain interference scores, pain intensity scores, and adverse outcomes were extracted. Multivariable linear regressions were performed to determine if preoperative weight loss correlated with patient-reported outcomes after controlling for confounders.
RESULTS: There were 90 patients, 75.6% women, who had a mean age of 65 years (range, 42-82) and were analyzed. There were 51 (56.7%) patients who underwent clinically relevant weight loss with a mean weight loss of 10.4% and experienced no difference in adverse outcomes. Preoperative weight loss predicted significantly improved 3-month postoperative physical function (β = 15.2 [13.0-17.3], P < .001), but not pain interference (β = -18.9 [-57.1-19.4], P = .215) or pain intensity (β = -1.8 [-4.9-1.2], P = .222) scores.
CONCLUSION: We found that medically supervised preoperative weight loss predicted improvement in physical function 3 months after TKA. This weight loss caused no major adverse effects. Further research is needed to understand the causal relationships between preoperative weight loss, medical supervision, and outcome after TKA and to elucidate potential longer-term benefits in a larger sample.
PURPOSE:To obtain a nonsteroidal anti-inflammatory of high safety with no side-effect, manifesting excellent action, using an alkane-1,2-diol. CONSTITUTION:An alkane-1,2-diol of the formula (n is 10-26) is mixed with usual excipient, binder, extender, disintegrator and other additives and made into preparations in usual manners to give the subject product. It can be prepared into tablets, granules, a powder, capsules, sugar-coated tablets, aqueous dispersion, emulsion, syrup, injection solution, external preparation and suppository. The dose is 0.1-1,000mg/kg/day for an adult in case of oral administration, and 0.01-1,000mg/kg/day for an adult in injection. When it is used externally, a preparation containing the compound in a concentration of 0.01-10wt.% is applied locally in an appropriate amount, when needed. It has anti- inflammatory, analgesic and antipyretic actions.
The current study has been designed as a randomized single-blind placebo-controlled clinical trial. Sample size calculation for the study was 18 newly diagnosed ALL children in each group using the numerical unpaired two groups data analysis formula. Subjects were recruited from newly diagnosed children with ALL and will start the induction phase of chemotherapy both in hospital ward and outpatient clinic in the Child Health Department at Cipto Mangunkusumo Hospital from August to December 2020. Subjects' parents received an explanation about the study, including the objective and benefits of the study, and also the procedure which will be held. Parents were then asked about the willingness to join the study and signed the form.

Subjects were randomized consecutively and distributed into two groups. Randomization was done by a third person to decide the distribution of the subjects based on the serial number of randomization. Subjects in treatment group will be given capsules containing 600 mg of NAC and subjects in the control group will be given capsules containing placebo (lactose) as the adjunctive treatment during the 6 week induction phase of chemotherapy. Both of the medicines were prepared by the Installation of Pharmacy in Cipto Mangunkusumo National Hospital with the same type and same color of capsules. NAC will be administered during the induction phase of chemotherapy starting in the first week until 6 weeks. This study will analyze change of MDA levels, transaminase enzyme levels, and bilirubin levels before and after the 6th week of the induction phase of chemotherapy.